American Conference Institute (ACI) will be holding is 15th Annual Summit on Biosimilars & Innovator Biologics: Legal, Regulatory, and Commercial Strategies for the Innovator and Biosimilars Marketplace on June 20-21, 2024 at the New York City Bar Association. Conference Co-Chairs are Deidre Parsons, Senior Director, Public Policy & Governmental Relations, Alnylam Therapeutics; Harshika Sarbajna, Vice President Commercial and Head Global, Alvotech; and Paki Banky, Director, Senior IP Counsel, IP Lead Cell and Gene at Novartis.
Conference attendees will hear from Administrative Patent Judges the Honorable Jacqueline Bonilla, Deputy Chief; the Honorable Linda Horner; and the Honorable Grace Obermann, as well as Supervisory Patent Examiner Vanessa Ford and Laurel Goldberg, Regulatory Counsel, CDER, Food and Drug Administration.
ACI faculty will offer presentations on the Biden Administration's initiatives on drugs and pricing strategies; an investors' roundtable on biosimilar valuation; the impact and insights for the future from Humira biosimilar launches; IPRs and policies and practices before the PTAB; and diversity, equity and inclusion in this industry, among others.
An agenda for the conference can be found here, including a complete brochure for this conference, detailed descriptions of conference sessions, list of speakers, and registration form. The registration fee is $2,395 for registration and payment by Mary 24, 2024; and $2,595 for payment by June 20th. Patent Docs readers are entitled to a 10% discount off registration using discount code D10-999-PD24. Those interested in registering for the conference can do so here, by emailing [email protected], or by calling 1-888-224-2480.
Patent Docs is a media partner of ACI's 15th Annual Summit on Biosimilars.
Comments